Rheumatoid Arthritis
Conditions
Brief summary
The purpose of this study is to determine the kinetics of change in quantitative measures of joint inflammation by state of the art power Doppler vascular imaging and to identify biomarkers in biological samples (synovial biopsies, DNA, RNA, PBMC, serum, plasma, urine and stool samples) from parallel cohorts of RA patients undergoing different treatments. This will be achieved implementing MSUS assessments, standard laboratories techniques (such as ELISAs, gene profiling, transcriptome analysis etc.) and the novel CyTOF™ technology.
Interventions
OTHERMusculoskeletal Ultrasound Imaging
B-mode and PD musculoskeletal ultrasound examination of selected joints.
OTHERSynovial biopsy
US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
Draw of research blood samples.
OTHERQuestionnaires
Administration of validated patients' questionnaires.
Sponsors
UCB Pharma
University of Oxford
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written confirmed diagnosis of Rheumatoid Arthritis as per ACR/EULAR 2010 criteria. * If patient is on oral corticosteroids, dose must be stable for 6 weeks prior to baseline visit. * Willingness and ability to comply with all the study procedures.
Exclusion criteria
* Any systemic inflammation conditions (other than RA), connective tissue disease or chronic pain disorders that may interfere with the interpretation of the outcome data. Examples include psoriatic arthritis, reactive arthritis, gout, systemic lupus erythematosus (SLE), polymyalgia rheumatic and/or temporal arteritis, Lyme's disease, fibromyalgia and chronic fatigue syndromes. * Major surgery planned within 8 weeks prior to screening or planned surgery throughout the study period. * Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 ≤ half-lives of the investigational drug, whichever is the longer). * Intramuscular/intra-articular glucocorticoids for 6 weeks prior to baseline visit. * Active infection. * Septic arthritis within a native joint within the last 12 months. * Sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ. * Known HIV or hepatitis B/C infection. * Latent TB infection unless they have completed adequate antibiotic prophylaxis. * Malignancy (other than basal cell carcinoma) within the last 10 years. * New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure. * Demyelinating disease. * Presence of a transplanted organ (with the exception of a corneal transplant \> 3 months prior to screening). * Known recent substance abuse (drug or alcohol).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in synovial thickness and vascularity using a limited joint set musculoskeletal ultrasound examination in Rheumatoid Arthritis. | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the distribution of cell populations in biological samples from Rheumatoid Arthritis patients using CyTOF. | 3 years |
| Changes in gene expression in biological samples from Rheumatoid Arthritis patients using gene profiling. | 3 years |
| Changes in cytokines' concentration in biological samples from Rheumatoid Arthritis patients using ELISA and transcriptome analysis. | 3 years |
Countries
United Kingdom
Outcome results
None listed